SG11202109932WA - Antibodies having specificity for btn2 and uses thereof - Google Patents

Antibodies having specificity for btn2 and uses thereof

Info

Publication number
SG11202109932WA
SG11202109932WA SG11202109932WA SG11202109932WA SG 11202109932W A SG11202109932W A SG 11202109932WA SG 11202109932W A SG11202109932W A SG 11202109932WA SG 11202109932W A SG11202109932W A SG 11202109932WA
Authority
SG
Singapore
Prior art keywords
btn2
specificity
antibodies
Prior art date
Application number
Inventor
Etienne Foucher
Carla Cano
Kieu Suong Le
Christine Pasero
Daniel Olive
Original Assignee
Imcheck Therapeutics Sas
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Inst Jean Paoli & Irene Calmettes
Univ Aix Marseille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcheck Therapeutics Sas, Inst Nat Sante Rech Med, Centre Nat Rech Scient, Inst Jean Paoli & Irene Calmettes, Univ Aix Marseille filed Critical Imcheck Therapeutics Sas
Publication of SG11202109932WA publication Critical patent/SG11202109932WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202109932W 2019-03-20 2020-03-20 Antibodies having specificity for btn2 and uses thereof SG11202109932WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305345 2019-03-20
EP19219691 2019-12-24
PCT/EP2020/057794 WO2020188086A1 (en) 2019-03-20 2020-03-20 Antibodies having specificity for btn2 and uses thereof

Publications (1)

Publication Number Publication Date
SG11202109932WA true SG11202109932WA (en) 2021-10-28

Family

ID=69810881

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109932W SG11202109932WA (en) 2019-03-20 2020-03-20 Antibodies having specificity for btn2 and uses thereof

Country Status (12)

Country Link
US (1) US20220162305A1 (en)
EP (1) EP3941940A1 (en)
JP (1) JP2022525937A (en)
KR (1) KR20220007041A (en)
CN (1) CN113811545A (en)
AU (1) AU2020243076A1 (en)
BR (1) BR112021018611A2 (en)
CA (1) CA3134122A1 (en)
IL (1) IL286486A (en)
MX (1) MX2021011334A (en)
SG (1) SG11202109932WA (en)
WO (1) WO2020188086A1 (en)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (en) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition for the production of therapeutic products in vivo.
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
ATE283926T1 (en) 1995-09-11 2004-12-15 Kyowa Hakko Kogyo Kk ANTIBODIES AGAINST THE ALPHA CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0971952A2 (en) 1997-04-10 2000-01-19 Royal Netherlands Academy of Arts and Sciences Diagnosis method and reagents
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
WO2006116192A2 (en) * 2005-04-21 2006-11-02 Medarex, Inc. Irta-1 antibodies and their uses
NZ614857A (en) 2007-03-29 2015-04-24 Genmab As Bispecific antibodies and methods for production thereof
WO2008145142A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
GB0717101D0 (en) * 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
SG10201800757TA (en) 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
WO2015077844A1 (en) * 2013-11-29 2015-06-04 Csl Limited Method of treating cancer
EP3319993B1 (en) * 2015-07-10 2020-01-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
US20230183346A1 (en) * 2016-02-26 2023-06-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
MX2020003219A (en) 2017-09-21 2020-07-20 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof.

Also Published As

Publication number Publication date
EP3941940A1 (en) 2022-01-26
CA3134122A1 (en) 2020-09-24
KR20220007041A (en) 2022-01-18
WO2020188086A1 (en) 2020-09-24
AU2020243076A1 (en) 2021-10-14
MX2021011334A (en) 2021-12-10
US20220162305A1 (en) 2022-05-26
JP2022525937A (en) 2022-05-20
BR112021018611A2 (en) 2021-11-23
CN113811545A (en) 2021-12-17
IL286486A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
SI3872091T1 (en) Antibodies against sars-cov-2
IL289585A (en) Dll3-targeting antibodies and uses thereof
IL289112A (en) Anti-tigit antibodies
IL275826A (en) Anti-mct1 antibodies and uses thereof
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
IL287690A (en) Anti-hvem antibodies and use thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL291068A (en) Anti-cd73 antibodies
IL284584A (en) Anti-tigit antibodies
IL289656A (en) Anti-tigit antibodies and application thereof
ZA202108836B (en) Anti-epha4 antibody
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
IL291550A (en) Anti-il-27 antibodies and uses thereof
GB201905150D0 (en) Ant-ige antibodies
GB201917480D0 (en) Antibodies
GB2581174B (en) Antibodies against hEPCR
GB201900732D0 (en) Antibodies
IL291280A (en) Anti-cd371 antibodies and uses thereof
IL290570A (en) Anti-cd19 antibodies and uses thereof
IL286803A (en) Anti-tauc3 antibodies and uses thereof
IL289160A (en) Anti-angpt2 antibodies
IL288935A (en) Novel cthrc1-specific antibody and use thereof
GB201902590D0 (en) Antibodies and uses thereof
IL286486A (en) Antibodies having specificity for btn2 and uses thereof
IL288807A (en) Anti-talen antibodies and uses thereof